Spots Global Cancer Trial Database for gp100 antigen
Every month we try and update this database with for gp100 antigen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | NCT00077532 | Melanoma (Skin) | gp100 antigen incomplete Freu... ipilimumab | 16 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00085397 | Melanoma (Skin) | autologous dend... gp100 antigen therapeutic aut... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | NCT00003229 | Melanoma (Skin) | aldesleukin gp100 antigen tyrosinase pept... | 18 Years - 75 Years | Duke University | |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00091338 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00006385 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... sargramostim tyrosinase pept... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00003568 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00003792 | Melanoma (Skin) | MART-1 antigen filgrastim flu matrix pept... gp100 antigen recombinant MAG... tyrosinase pept... in vitro-treate... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma | NCT00019175 | Melanoma (Skin) | aldesleukin fowlpox virus v... gp100 antigen | 18 Years - | National Cancer Institute (NCI) | |
| LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | NCT00295958 | Melanoma (Skin) Non-melanomatou... | LMB-2 immunotox... MART-1 antigen gp100 antigen incomplete Freu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma | NCT00019175 | Melanoma (Skin) | aldesleukin fowlpox virus v... gp100 antigen | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma | NCT00003362 | Melanoma (Skin) | QS21 gp100 antigen incomplete Freu... sargramostim tyrosinase pept... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma | NCT00072085 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | NCT00003229 | Melanoma (Skin) | aldesleukin gp100 antigen tyrosinase pept... | 18 Years - 75 Years | Duke University | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Vaccine Therapy in Treating Patients With Stage IV Melanoma | NCT00003665 | Melanoma (Skin) | dendritic cell-... gp100 antigen therapeutic tum... tyrosinase pept... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma | NCT00003897 | Melanoma (Skin) | gp100 antigen sargramostim | 18 Years - 120 Years | University of Wisconsin, Madison | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma | NCT00019175 | Melanoma (Skin) | aldesleukin fowlpox virus v... gp100 antigen | 18 Years - | National Cancer Institute (NCI) | |
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | NCT00470015 | Melanoma (Skin) | MART-1 antigen IL-2 gp100 antigen GM-CSF MART-1a peptide | 18 Years - 120 Years | Mayo Clinic | |
| Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00006113 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen recombinant CD4... recombinant int... recombinant int... sargramostim therapeutic aut... therapeutic tum... tyrosinase pept... Candida albican... | 18 Years - | University of Southern California | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00003792 | Melanoma (Skin) | MART-1 antigen filgrastim flu matrix pept... gp100 antigen recombinant MAG... tyrosinase pept... in vitro-treate... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | NCT00010309 | Melanoma (Skin) | MART-1 antigen gp100 antigen | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00091338 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | NCT00019682 | Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Aldesleukin gp100 Antigen Montanide ISA 5... Quality-of-Life... Questionnaire A... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | NCT00470015 | Melanoma (Skin) | MART-1 antigen IL-2 gp100 antigen GM-CSF MART-1a peptide | 18 Years - 120 Years | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
